Bristol-Myers Squibb’s Eliquis Has Added Over $1 Billion In Sales Each Year, But Can This Trend Continue?

August 23rd, 2019 by Trefis Team
+10.80%
Upside
57.28
Market
63.47
Trefis
BMY: Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb

Bristol-Myers Squibb’s (NYSE:BMY) Eliquis is a leading novel oral anticoagulant, which refers to blood thinners that treats, prevents, and reduces the risk of blood clotting. Other NOACs include Johnson & Johnson’s Xarelto, Boehringer Ingelheim’s Pradaxa, Daiichi Sankyo’s Lixiana and Savaysa, and Portola’s Bevyxxa. Eliquis has seen stellar growth in recent years, led by increased acceptance among the physicians, which has led to the drug becoming the market leader in total prescriptions. Eliquis has added over $1 billion in sales each year since 2014.  While the strong growth could continue for Eliquis in the coming years, it may not add $1 billion plus in sales each year.  The drug’s patent is protected till 2026, and it is estimated that the drug’s revenues could grow at a CAGR of 11% over the next few years. In this note and linked dashboard, we discuss how Eliquis is placed in the anticoagulants market. You can look at our interactive dashboard analysis ~ Eliquis Gave Bristol-Myers Squibb (BMY) $1B in New Revenues Each Year: Is the Party Ending Soon? ~ for more details. In addition, you can see more Healthcare Data here.

Bristol-Myers Squibb’s Eliquis Is Top Selling NOAC Followed By Johnson & Johnson’s Xarelto

Relevant Articles
  1. Pick BMY Stock Over JNJ?
  2. AbbVie’s Pain Is BMY’s Gain
  3. Should You Pick Bristol Myers Squibb Stock At $55?
  4. What Cobenfy Approval Means For Bristol Myers Squibb Stock
  5. Should You Pick Bristol Myers Squibb Stock Over AbbVie?
  6. Should You Pick Bristol Myers Squibb Stock At $50 After A Solid Q2 Beat?

Combined Sales of The NOACs Above Grew From $3.9 Billion In 2014 To $11.8 Billion In 2018. Eliquis’ Share Increased From 20% To 54% During The Same Period, As The Drug Saw Stellar Growth In The Recent Years. The Drug’s Share Could Further Increase To 57%, As It Continues To See Higher Acceptance.

  • Total NOAC market, which includes Xarelto, Eliquis, Pradaxa, Bevyxxa, Lixiana, and Savaysa has grown from $3.9 billion in 2014 to $11.8 billion in 2018.
  • Of which, Eliquis’ sales grew from $774 million to $6.4 billion, representing market share growth from 20% to 54%, during the same period.
  • Looking forward, total market sales could grow to $15.3 billion, and Eliquis’ share could be close to 60% by 2021.

Eliquis’ Patent Is Protected Till 2026 While Xarelto And Others Will See Patent Losses Earlier, As Shown Below

  • Eliquis: 2026
  • Xarelto: 2024
  • Pradaxa: 2021
  • Bevyxxa: 2020
  • Lixiana and Savaysa: 2023

Eliquis Accounted For 28% of Bristol-Myers Squibb’s Total Sales In 2018, And The Contribution Could Increase In The Coming Years

  • Bristol-Myers Squibb’s total sales grew from $15.9 billion in 2014 to $22.6 billion in 2018.
  • Eliquis’ contribution to the company’s top line growth was significant.
  • It accounted for a mere 5% to the company’s total sales in 2014, but that figure increased to 29% in 2018.
  • We forecast Bristol-Myers Squibb’s revenues to grow to north of $24 billion by 2021.
  • Eliquis’ sales will likely grow at a faster pace than the overall company’s, and it could account for close to 37% of the company’s total sales in 2021.

 

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

All Trefis Data

Like our charts? Explore example interactive dashboards and create your own.